DiaMedica Therapeutics Inc

NASDAQ DMAC

Data sourced from iex and EODHD
Download Data

DiaMedica Therapeutics Inc Market Capitalization on June 03, 2024: USD 111.99 M

DiaMedica Therapeutics Inc Market Capitalization is USD 111.99 M on June 03, 2024, a 9.29% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.
  • DiaMedica Therapeutics Inc 52-week high Market Capitalization is USD 167.00 M on June 26, 2023, which is 49.11% above the current Market Capitalization.
  • DiaMedica Therapeutics Inc 52-week low Market Capitalization is USD 114.22 K on May 03, 2024, which is -99.90% below the current Market Capitalization.
  • DiaMedica Therapeutics Inc average Market Capitalization for the last 52 weeks is USD 109.99 M.
NASDAQ: DMAC

DiaMedica Therapeutics Inc

CEO Mr. Dietrich John Pauls MBA
IPO Date Jan. 4, 2008
Location United States
Headquarters Two Carlson Parkway, Minneapolis, MN, United States, 55447
Employees 18
Sector Healthcare
Industry Biotechnology
Description

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Similar companies

MIST

Milestone Pharmaceuticals Inc

NA

NA

CNTA

Centessa Pharmaceuticals PLC ADR

NA

NA

DAWN

Day One Biopharmaceuticals Inc

NA

NA

StockViz Staff

September 16, 2024

Any question? Send us an email